Caring for people with diabetic foot ulcers costs NHS England the region of £1 billion a year, but the developer of a new digital tool says it could help reduce the burden.
Novo Nordisk’s bid to disrupt the diabetes market with an oral formulation of its GLP-1 agonist semaglutide has advanced again with new data showing it is safe for the heart.
The American Diabetes Association (ADA) annual conference has dominated the medical research headlines this weekend as pharma and biotech firms unveiled latest data from therapies for
After moving from academia to industry, Stephen Gough is now Novo Nordisk’s global chief medical officer, working on putting patients at the centre of the company and providing medical lead
It may be possible to design drugs that mimic the positive health benefits of gut bacteria to treat diseases such as type II diabetes, a new study has found.
Johnson & Johnson’s Janssen pharma unit has announced new results showing that its Invokana diabetes medicine is the first in nearly 20 years to significantly reduce risk of renal failu
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.